Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A new oral option for hereditary angioedema is showing injectable-level results. The phase 3 CHAPTER-3 trial found that once-daily deucrictibant extended-release tablets cut monthly HAE attack rates by 83% versus placebo — and nearly half of patients on the drug were completely attack-free. If approved, it could offer patients a far more convenient alternative to subcutaneous injections.
A once-daily oral pill may soon give hereditary angioedema (HAE) patients the kind of attack protection previously only seen with injectable therapies. The phase 3 CHAPTER-3 trial found that deucrictibant extended-release (XR) — a bradykinin B2 receptor antagonist developed by Pharvaris — reduced monthly HAE attack rates by 83% compared to placebo over 24 weeks. Crucially, that reduction kicked in within the first week and held steady throughout the study.
The results are a meaningful step forward because the only currently approved targeted oral HAE prophylactic, berotralstat, has shown comparatively modest efficacy versus subcutaneous options. Deucrictibant XR also demonstrated significantly better quality-of-life scores across all domains, including functioning, fatigue, and nutrition. A separate phase 3 trial (RAPIDe-3) showed that the immediate-release version of the drug, taken on-demand during acute attacks, cut median time to symptom relief from over 12 hours (placebo) to just 1.28 hours — with an FDA decision expected by April 2027.
By the Numbers:
Why it matters: HAE patients often face a trade-off between the convenience of oral medications and the superior efficacy of injectables. Deucrictibant XR appears to close that gap — potentially offering patients a portable, once-daily pill that delivers results on par with subcutaneous drugs, with a favorable safety profile and no significant cardiovascular or GI concerns.